scanX
Lupin
add_icon

Lupin

2,113.90
+32.10
(1.54%)
Market Cap
₹96,553.34 Cr
PE Ratio
21.86
Volume
5,74,240.00
Day High - Low
₹2,117.20 - ₹2,080.00
52W High-Low
₹2,402.90 - ₹1,795.20
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
96,553.34 Cr
EPS
71.95
PB Ratio
4.84
Book Value
429.79
EBITDA
5,479.10
Dividend Yield
0.58 %
Industry
Healthcare
Sector
Pharmaceuticals
ROE Growth %
-
Debt to Equity
0.27
Analyst Rating and Forecast
- By Refinitiv from36 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell+8.33 %
+8.33 %
Forecast For
Actual

Company News

View All News
Caret
positive
Lupin Manufacturing Solutions Partners with PolyPeptide1 day ago
Lupin Manufacturing Solutions announces strategic alliance with PolyPeptide Group AG to enhance global peptide supply chain resilience and accelerate readiness for expanding peptide therapeutics market.
neutral
Lupin Allots 36,626 Equity Shares Under Employee Stock Option Plan3 days ago
Lupin's Operations and Finance Committee allotted 36,626 fully paid-up equity shares of ₹2 each to employees and subsidiary staff who exercised vested stock options. The allotment increased the company's issued and paid-up share capital to ₹91,35,97,612, comprising 45,67,98,806 equity shares of ₹2 each.
positive
Lupin Receives Tentative FDA Approval for Siponimod Tablets Generic Version9 days ago
Lupin Limited received tentative approval from the U.S. FDA for its generic version of Siponimod Tablets in 0.25mg, 1mg and 2mg strengths, bioequivalent to Novartis' Mayzent for treating relapsing forms of multiple sclerosis. The product will be manufactured at Lupin's Pithampur facility in India and targets a market with estimated annual sales of USD 195 million in the U.S.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,793.50
#1 4,30,320.73
41.35
#1 54,729.00
9.71
#1 10,980
2.89
56.39
Divis Laboratories
6,426.50
1,70,603.38
68.71
9,712.00
18.67
2,191
35.10
49.16
Torrent Pharmaceuticals
3,791.50
1,28,321.59
60.12
11,539.40
6.99
1,911
30.46
59.20
Cipla
1,517.40
1,22,568.60
22.48
28,409.50
7.12
5,291
3.71
49.51
Dr Reddys Laboratories
1,279.30
1,06,772.14
18.52
33,741.20
16.73
5,725
-0.38
59.83
Lupin
2,113.90
#6 96,553.34
#4 21.86
#6 22,909.50
#5 13.74
#6 3,306
#1 72.75
65.41
Zydus Life Science
929.15
93,494.23
#1 18.46
23,511.00
18.55
4,615
34.60
42.49
Mankind Pharma
2,178.80
89,931.82
50.42
12,744.20
#1 20.90
2,007
-21.05
34.32
Aurobindo Pharma
1,195.10
69,411.60
19.91
32,345.60
9.43
3,484
3.81
52.36
Alkem Laboratories
5,631.00
67,327.05
27.91
13,458.30
3.70
2,216
10.98
49.02
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
5,619
6,243
6,921
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
4,346
4,541
4,706
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
1,273
1,702
2,215
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
22 %
26 %
31 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
393
299
317
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
89
92
108
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
896
1,416
2,007
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
114
194
522
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
782
1,222
1,485
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75
16.93
26.70
32.36
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
9,719
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
16,799
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
517
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
1,146
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
17,823
Total Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
8,961
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
2,949
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
17,294
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
17,112
Share Capital
90
90
90
90
91
91
91
91
91
91
91
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
560
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
-4,172
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
3,000
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184
1,732
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
46.92 %
46.90 %
46.90 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
21.46 %
21.25 %
20.49 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
25.41 %
25.56 %
26.55 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
5.10 %
5.23 %
5.12 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
1.10 %
1.05 %
0.94 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988
2,83,210
2,86,604
2,80,256

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 7.5 5 5 6 6.5 4 4 8 12
Dividend Yield (%) 0.00 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.57

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 Jul 2021 DIVIDEND Dividend
₹ 6.50 /share
 27 Jul 2021 1,212.25 1,111.60
15 Jul 2022 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2022 683.30 643.20
14 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2023 732.25 930.75
16 Jul 2024 DIVIDEND Dividend
₹ 8.00 /share
 16 Jul 2024 1,655.25 1,832.10
02 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 02 Aug 2024 1,778.90 1,953.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 2,151.95 2,166.05
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Feb 2025 2,134.25 2,169.40
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 May 2025 2,107.70 2,063.00
25 Jul 2025 DIVIDEND Dividend
₹ 12.00 /share
 25 Jul 2025 2,063.00 1,943.40
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,930.85 1,882.20
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Aug 2025 1,894.70 1,918.00
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2025 1,943.35 1,997.00

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Newspaper Publication For The Information Regarding Special Window For Re-Lodgement For Transfer Request Of Physical Shares.2 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS3 days ago
ESG Rating By NSE Sustainability Ratings & Analytics Limited.4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Dec 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 28, 2025
U.S. FDA Has Conducted An Inspection At Companys Manufacturing Facility Located At Goa India.Nov 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Board Meeting Outcome for Outcome Of The Board Meeting For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2025
Board Meeting Intimation for Considering And Taking On Record The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.Oct 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 13, 2025
U.S. FDA Has Conducted A Pre-Approval Inspection At The Companys Manufacturing Facility Located In Somerset New Jersey U.S.A.Oct 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
U.S. FDA Has Determined The Inspection Of Companys Pithampur Unit-2 Manufacturing Facility As Official Action Indicated.Oct 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 30, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Announcement under Regulation 30 (LODR)-AcquisitionSep 29, 2025
Closure of Trading WindowSep 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 25, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotSep 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 23, 2025
U.S. FDA Has Conducted A Product-Specific Pre-Approval Inspection At The CompanyS Pune Biotech Facility.Sep 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Quant ELSS Tax Saver Fund Direct-Growth
0.00%
-850402
-1.34%
-1.37%
ICICI Prudential Equity Arbitrage Direct-Growth
0.40%
-789650
-0.46%
-0.34%
Invesco India Arbitrage Fund Direct-Growth
0.02%
-753525
-0.54%
-0.53%
Quant Flexi Cap Fund Direct-Growth
0.00%
-619821
-1.77%
-1.75%
UTI Large Cap Fund Direct-Growth
0.93%
600344
0.93%
0.93%
Quant Mid Cap Fund Direct-Growth
0.00%
-431026
-0.99%
-1.00%
Tata Aggressive Hybrid Fund Direct-Growth
0.00%
-250000
-1.18%
-1.19%
Sundaram Aggressive Hybrid Fund Direct-Growth
0.00%
-238745
-0.64%
-0.66%
Quant Multi Cap Fund Direct-Growth
0.00%
-237329
-0.50%
-0.49%
Bandhan Large & Mid Cap Fund Direct-Growth
1.28%
204080
0.31%
0.54%
Tata Mid Cap Direct Plan-Growth
1.54%
-200000
-0.69%
-0.73%
Quant Large and Mid Cap Fund Direct-Growth
0.00%
-198273
-1.10%
-1.09%
UTI Mid Cap Fund Direct-Growth
1.33%
190000
0.39%
0.51%
Kotak Arbitrage Fund Direct-Growth
0.50%
189975
0.08%
0.03%
Canara Robeco Large and Mid Cap Fund Direct-Growth
0.32%
184706
0.16%
0.16%
Axis Midcap Direct Plan-Growth
0.95%
-173819
-0.06%
-0.11%
DSP Equity Opportunities Fund Direct Plan-Growth
1.32%
171106
0.22%
0.21%
Tata Arbitrage Fund Direct - Growth
0.49%
-167025
-0.14%
0.08%
SBI Arbitrage Opportunities Fund Direct-Growth
0.65%
-164475
-0.06%
-0.02%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.04%
-156825
-0.13%
-0.19%
ICICI Prudential Focused Equity Fund Direct-Growth
2.68%
-153079
-0.20%
-0.48%
Bandhan Flexi Cap Fund Direct-Growth
0.00%
-150000
-0.39%
-0.39%
Bandhan Value Fund Direct-Growth
0.90%
-125000
-0.20%
-0.21%
JM Midcap Fund Direct - Growth
2.82%
125000
1.83%
2.82%
ICICI Prudential Children's Fund Direct-Growth
1.81%
123878
1.81%
1.81%

Technical Indicators

RSI(14)
Neutral
65.41
ATR(14)
Volatile
35.71
STOCH(9,6)
Neutral
58.08
STOCH RSI(14)
Neutral
51.65
MACD(12,26)
Bearish
-0.79
ADX(14)
Weak Trend
18.80
UO(9)
Bearish
60.91
ROC(12)
Uptrend And Accelerating
2.04
WillR(14)
Overbought
-2.84
Bearish
3
Neutral
5
Bullish
1

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Website
https://www.lupin.com/
Chairperson NameM D Gupta
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104